Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab versus standard chemotherapy in previously treated advanced malignant pleural mesothelioma
2016-002062-31Phase 3Unknown
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Feb 2017
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab, gemcitabine and vinorelbine in pleural mesothelioma (2 arms), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2016-002062-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002062-31.